Metastatic Mucinous Ovarian Cancer and Treatment Decisions Based on Histology and Molecular Markers Rather Than the Primary Location

Restricted access

Approximately 22,000 cases of ovarian cancer occur each year in the United States, and likely fewer than 2000 cases of mucinous ovarian cancers. Although 90% of patients with mucinous ovarian cancer present with stage I disease and have curative surgeries, advanced-stage disease is known to have a poor response to standard platinum- and taxane-based chemotherapy. Despite limited enthusiasm, standard chemotherapy is still recommended for most patients with advanced-stage mucinous malignancies of the ovary. This report presents an unusual case of a woman with HER2-positive metastatic mucinous carcinoma of the ovary treated with chemotherapy regimens typically used for colorectal malignancies, followed by epidermal growth factor receptor–targeted therapies.

Correspondence: Angela Jain, MD, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA 19111. E-mail: Angela.Jain@fccc.edu
  • 1

    VergoteIDe BrabanterJFylesA. Prognostic importance of degree of differentiation and cyst rupture in stage I invasive epithelial ovarian carcinoma. Lancet2001;357:176182.

    • Search Google Scholar
    • Export Citation
  • 2

    International Collaborative Ovarian Neoplasm Group. Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON 3 randomised trial. Lancet2002;360:505515.

    • Search Google Scholar
    • Export Citation
  • 3

    HessVA’HernRNasiriN. Mucinous epithelial ovarian cancer: a separate entity requiring specific treatment. J Clin Oncol2004;22:10401044.

    • Search Google Scholar
    • Export Citation
  • 4

    MorganRJAlvarezRDArmstrongDK. NCCN Clinical Practice Guidelines in Oncology: Ovarian Cancer. Version 32012. Available at: NCCN.org. Accessed July 26 2012.

    • Search Google Scholar
    • Export Citation
  • 5

    HarrisonMLJamesonCGoreME. Mucinous ovarian cancer. Int J Gynecol Cancer2008;18:209214.

  • 6

    McBroomJWParkerMFKrivakTC. Primary appendiceal malignancy mimicking advanced stage ovarian carcinoma: a case series. Gynecol Oncol2000;78:388390.

    • Search Google Scholar
    • Export Citation
  • 7

    SeidmanJDKurmanRJRonnettBM. Primary and metastatic mucinous adenocarcinomas in the ovaries: incidence in routine practice with a new approach to improve intraoperative diagnosis. Am J Surg Pathol2003;27:985993.

    • Search Google Scholar
    • Export Citation
  • 8

    AlexandreJRay-CoquardISelleF. Mucinous advanced epithelial ovarian carcinoma: clinical presentation and sensitivity to platinum–paclitaxel-based chemotherapy, the GINECO experience. Ann Oncol2010;21:23772381.

    • Search Google Scholar
    • Export Citation
  • 9

    HeideIThiedeCSonntagTThe status of p53 in the metastatic progression of colorectal cancer. Eur J Cancer1997;33:13141322.

  • 10

    LopezIP OliveiraLTucciP. Differrent mutation profiles associated to p53 accumulation in colorectal cancer. Gene2012;499:8187.

  • 11

    MunroAJLainSLaneDP. P53 abnormalities and outcomes in colorectal cancer: a systematic review. Br J Cancer2005;92:434444.

  • 12

    Cancer Genome Atlas Research Network. Integrated genomic analysis of ovarian carcinoma. Nature2011;474:609615.

  • 13

    HavrileskyLDarcyMHamdanH. Prognostic significance of p53 mutation and p53 overexpression in advanced epithelial ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol2003;21:38143825.

    • Search Google Scholar
    • Export Citation
  • 14

    SatoSItamochiHKigawaJCombination chemotherapy of oxaliplatin and 5-fluorouracil may be an effective regimen for mucinous adenocarcinoma of the ovary: a potential treatment strategy. Cancer Sci2008;100:546551.

    • Search Google Scholar
    • Export Citation
  • 15

    Di FioreFBlanchardFCharbonnierF. Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by cetuximab plus chemotherapy. Br J Cancer2007;96:11661169.

    • Search Google Scholar
    • Export Citation
  • 16

    AmadoRGWolfMPeetersM. Wild type kras status is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol2008;26:16261634.

    • Search Google Scholar
    • Export Citation
  • 17

    Van CutsemEKohneCHHitreE. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med2009;360:14081417.

    • Search Google Scholar
    • Export Citation
  • 18

    CuatrecasasMVillaneuvaAMatias-GuiuXPratJ. K-ras mutations in mucinous ovarian tumors. A clinicopathologic and molecular study in 95 cases. Cancer1997;79:15811586.

    • Search Google Scholar
    • Export Citation
  • 19

    SchilderRJPathakHBLokshinAE. Phase II trial of single agent cetuximab in patients with persistent or recurrent epithelial ovarian or primary peritoneal carcinoma with the potential for dose escalation to rash. Gyn Oncol2009;113:2127.

    • Search Google Scholar
    • Export Citation
  • 20

    LiQWangDLiJChenP. Clinicopathological and prognostic significance of HER-2/neu and VEGF expression in colon carcinomas. BMC Cancer2011;11:277.

    • Search Google Scholar
    • Export Citation
  • 21

    LeeCHHuntsmanDGCheangMC. Assessment of Her-1, Her-2, and Her-3 expression and Her-2 amplification in advanced stage ovarian carcinoma. Int J Gynec Pathol2008;27:161174.

    • Search Google Scholar
    • Export Citation
  • 22

    SorscherSM. Marked response to single agent trastuzumab in a patient with metastatic HER-2 gene amplified rectal cancer. Cancer Invest2011;29:456459.

    • Search Google Scholar
    • Export Citation
  • 23

    McAlpineJNWiegandKCVangR. HER-2 overexpression and amplification is present in a subset of ovarian mucinous carcinomas and can be targeted with trastuzumab therapy. BMC Cancer2009;9:433444.

    • Search Google Scholar
    • Export Citation
  • 24

    BlackwellKLBursteinHJStornioloAM. Randomized study of lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer. J Clin Oncol2010;28:11241130.

    • Search Google Scholar
    • Export Citation
  • 25

    ShimizuYUmezawaSHasumiK. A phase II study of combined CPT-11 and mitomycin-c in platinum refractory clear cell and mucinous ovarian carcinoma. Ann Acad Med Singapore1998;27:650656.

    • Search Google Scholar
    • Export Citation
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 238 237 9
PDF Downloads 27 27 0
EPUB Downloads 0 0 0